Danaher to buy Abcam in deal valued at $5.7 billion By Reuters
1 min read
© Reuters.
(Reuters) -Danaher Corp said on Monday it would buy medical equipment vendor Abcam Plc in a deal valued at $5.7 billion including debt, to expand its portfolio of biomedical services.
Danaher (NYSE:) will pay $24 per share in cash, a 2.7% premium to Abcam’s last closing price.
Abcam shares rose 3.9% higher on Friday after Reuters reported Danaher was in the lead to acquire the company.
Danaher, one of the world’s largest suppliers of diagnostic tools with a market value of $190 billion, has turned to dealmaking to expand in the sector. Abcam’s antibody and reagent solutions could help Danaher win more and bigger contracts with some customers.
